The Preferred Biotech Resource in Asia-Pacific
Vol 19, No 07, July 2015
Biotech in China
Kh-biotech cover


Eye on China


Conferences ListingConferences

Pharma Sales
Admedus releases interim phase I results for Herpes study
Interim study results on Admedus's Phase 1 trial of a therapeutic vaccine for Herpes Simplex Virus (HSV-2) have shown that it achieved the primary endpoint of the study by being safe in the study subjects. In addition, the study has also shown that the vaccine was able to generate a T-cell response.

Admedus is a diversified healthcare company focused on investing in and developing next generation technologies, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical sales and distribution business.

"This is an encouraging result for the core vaccine technology and provides us with the basis for not only progressing the Herpes therapeutic vaccine program, but also preparing the Human Papillomavirus vaccine for initial clinical studies as a therapeutic against HPV and Cervical Cancer." said Admedus CEO Mr Lee Rodne.

The core technology is based on Professor Ian Frazer and his team's work over the last 10 years. The technology looks at stimulating the immune response to enable a patient to fight against diseases.

"The results are very encouraging and we believe we should progress these programs forward," said Professor Ian Frazer.

"Once we complete our analysis the team will be looking to take this program into a second clinical study in patients infected with the Herpes virus".

Currently there is no cure for Herpes and incidence is high. The US CDC estimates that 1 in 6 people in the USA between the age of 14 and 49 have contracted the infection. There is currently no cure for Herpes Simplex 2 infection.

Click here for the complete issue.